Aarti Drugs Limited (NSE:AARTIDRUGS)
India · Delayed Price · Currency is INR 378.40
+12.50 (3.42%)
May 19, 2026, 3:29 PM IST
Aarti Drugs Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 25,653 | 23,870 | 25,286 | 27,161 | 24,886 |
Other Revenue | 23.9 | - | - | - | 0 |
| 25,677 | 23,870 | 25,286 | 27,161 | 24,886 | |
Revenue Growth (YoY) | 7.57% | -5.60% | -6.90% | 9.14% | 15.49% |
Cost of Revenue | 16,187 | 15,614 | 16,970 | 19,102 | 17,022 |
Gross Profit | 9,490 | 8,256 | 8,316 | 8,058 | 7,865 |
Selling, General & Admin | 1,293 | 1,141 | 1,047 | 933.07 | 840.53 |
Other Operating Expenses | 5,081 | 4,244 | 4,104 | 4,069 | 3,640 |
Operating Expenses | 7,044 | 5,943 | 5,666 | 5,505 | 4,981 |
Operating Income | 2,446 | 2,313 | 2,650 | 2,553 | 2,884 |
Interest Expense | -337.1 | -358.73 | -335.15 | -332.93 | -207.48 |
Interest & Investment Income | - | 124.09 | 24.97 | 7.02 | 23.16 |
Other Non Operating Income (Expenses) | 0 | 39.51 | 15.33 | 14.92 | 0 |
EBT Excluding Unusual Items | 2,109 | 2,118 | 2,355 | 2,242 | 2,700 |
Pretax Income | 2,109 | 2,118 | 2,355 | 2,242 | 2,700 |
Income Tax Expense | 159.7 | 436.74 | 639.37 | 578.25 | 649.59 |
Earnings From Continuing Operations | 1,949 | 1,681 | 1,716 | 1,664 | 2,050 |
Minority Interest in Earnings | -0.2 | 0.62 | -1.73 | -0.48 | 0.43 |
Net Income | 1,949 | 1,682 | 1,714 | 1,663 | 2,050 |
Net Income to Common | 1,949 | 1,682 | 1,714 | 1,663 | 2,050 |
Net Income Growth | 15.91% | -1.90% | 3.07% | -18.89% | -26.88% |
Shares Outstanding (Basic) | 91 | 91 | 92 | 93 | 93 |
Shares Outstanding (Diluted) | 91 | 91 | 92 | 93 | 93 |
Shares Change (YoY) | -0.02% | -0.72% | -0.72% | - | -0.64% |
EPS (Basic) | 21.36 | 18.42 | 18.65 | 17.96 | 22.14 |
EPS (Diluted) | 21.36 | 18.42 | 18.65 | 17.96 | 22.14 |
EPS Growth | 15.93% | -1.19% | 3.82% | -18.89% | -26.41% |
Free Cash Flow | 802.2 | 674.22 | 1,326 | -314.97 | -815.61 |
Free Cash Flow Per Share | 8.79 | 7.39 | 14.42 | -3.40 | -8.81 |
Dividend Per Share | - | 1.000 | 1.000 | 1.000 | 1.000 |
Dividend Growth | - | - | - | - | -60.00% |
Gross Margin | 36.96% | 34.59% | 32.89% | 29.67% | 31.60% |
Operating Margin | 9.53% | 9.69% | 10.48% | 9.40% | 11.59% |
Profit Margin | 7.59% | 7.04% | 6.78% | 6.12% | 8.24% |
Free Cash Flow Margin | 3.12% | 2.83% | 5.24% | -1.16% | -3.28% |
EBITDA | 3,116 | 2,843 | 3,140 | 3,028 | 3,353 |
EBITDA Margin | 12.13% | 11.91% | 12.42% | 11.15% | 13.47% |
D&A For EBITDA | 669.7 | 530.44 | 489.77 | 475.43 | 469.4 |
EBIT | 2,446 | 2,313 | 2,650 | 2,553 | 2,884 |
EBIT Margin | 9.53% | 9.69% | 10.48% | 9.40% | 11.59% |
Effective Tax Rate | 7.57% | 20.62% | 27.15% | 25.79% | 24.06% |
Revenue as Reported | 25,677 | 24,034 | 25,326 | 27,182 | 25,000 |
Advertising Expenses | - | 17.91 | 23.3 | 11.67 | 13.5 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.